Noninvasive detection of COPD and Lung Cancer through breath analysis using MOS Sensor array based e-nose

Author(s):  
Binson V A ◽  
M. Subramoniam ◽  
Luke Mathew
CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 774A
Author(s):  
Peter J. Mazzone ◽  
Xiaofeng Wang ◽  
Yaomin Xu ◽  
Tarek Mekhail ◽  
Mary Beukemann ◽  
...  

2019 ◽  
Vol 8 (2) ◽  
pp. 4279-4283

An endeavor to reproduce the Exhaled Breath Analysis with a colorimetric Sensor Array for the distinguishing proof and portrayal of lung Cancer by Peter J. Mazzone yet duplicated in urban situations, to survey the legitimacy of the etod of distinguishing biosignatures in the breath of individuals and furthermore including clinical hazard factors To be as true as possible to the original experiment by developing an breath biosignature of lung malignant growth utilizing a colorimetric sensor cluster and to decide the exactness of breath biosignatures of lung disease but this time concentrated only around sample concentrated from urban areas Comparative techniques were utilized as refered to unique analysis The breathed out breath of 200 investigation subjects, 80 with lung malignant growth and 120 controls, was strained over a colorimetric sensor cluster. Expectation copies were constructed and factually rechecked dependent on the shading deviations of the sensor. Age, sex, contamination introduction, zone of remain, smoking history, and interminable uncooperative pneumonic sickness were fused in the forecast representations. The conjecture model were first endorsed in real way,The show were made of the combined breath and clinical biosignature ; was similarly precise at perceiving lung sickness from control subjects (C-estimation 0.811). The precision improved when the model focused on only a solitary histology (C-estimation 0.825–0.890). Individuals with different histologists could be definitely perceived from one another (C-estimation 0.864 for adenocarcinoma versus squamous cell carcinoma). Moderate rightness were noted for affirmed breath biosignatures of stage and survival. Conclusions: A colorimetric sensor array offers a possible tool to detect any sings especially of lung cancer derived from biosignatures of exhaled breath. Though the extent of surety changes with optimizations, yet breath can be evaluated successfully by evaluating specific factors such as incorporating clinical risk factors.


2016 ◽  
Vol 10 (2) ◽  
pp. 026012 ◽  
Author(s):  
Tali Feinberg ◽  
Layah Alkoby-Meshulam ◽  
Jens Herbig ◽  
John C Cancilla ◽  
Jose S Torrecilla ◽  
...  

ETRI Journal ◽  
2018 ◽  
Vol 40 (6) ◽  
pp. 802-812 ◽  
Author(s):  
Jin-Young Jeon ◽  
Jang-Sik Choi ◽  
Joon-Boo Yu ◽  
Hae-Ryong Lee ◽  
Byoung Kuk Jang ◽  
...  

Chemosensors ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 209
Author(s):  
Davide Marzorati ◽  
Luca Mainardi ◽  
Giulia Sedda ◽  
Roberto Gasparri ◽  
Lorenzo Spaggiari ◽  
...  

Lung cancer is characterized by a tremendously high mortality rate and a low 5-year survival rate when diagnosed at a late stage. Early diagnosis of lung cancer drastically reduces its mortality rate and improves survival. Exhaled breath analysis could offer a tool to clinicians to improve the ability to detect lung cancer at an early stage, thus leading to a reduction in the associated survival rate. In this paper, we present an electronic nose for the automatic analysis of exhaled breath. A total of five a-specific gas sensors were embedded in the electronic nose, making it sensitive to different volatile organic compounds (VOCs) contained in exhaled breath. Nine features were extracted from each gas sensor response to exhaled breath, identifying the subject breathprint. We tested the electronic nose on a cohort of 80 subjects, equally split between lung cancer and at-risk control subjects. Including gas sensor features and clinical features in a classification model, recall, precision, and accuracy of 78%, 80%, and 77% were reached using a fourfold cross-validation approach. The addition of other a-specific gas sensors, or of sensors specific to certain compounds, could improve the classification accuracy, therefore allowing for the development of a clinical tool to be integrated in the clinical pipeline for exhaled breath analysis and lung cancer early diagnosis.


Sign in / Sign up

Export Citation Format

Share Document